
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
A U.S. District Judge has sustained plaintiff's complaint against the manufacturers of the LHRH agonist leuprolide acetate (Lupron), for improper pricing activities.





